

# Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on $\beta$ 2 adrenoceptor

Mireia Jiménez-Rosés<sup>1,2</sup>  | Bradley Angus Morgan<sup>1,3,4,5</sup> | Maria Jimenez Sigstad<sup>1,2</sup> |  
 Thuy Duong Zoe Tran<sup>1,6</sup> | Rohini Srivastava<sup>1,6</sup> | Asuman Bunsuz<sup>1,2</sup> |  
 Leire Borrega-Román<sup>1,2,7,8</sup> | Pattarin Hompluem<sup>1,2</sup> | Sean A. Cullum<sup>1,2,5</sup> |  
 Clare R. Harwood<sup>1,2,5</sup> | Eline J. Koers<sup>1,2</sup>  | David A. Sykes<sup>1,2</sup>  | Iain B. Styles<sup>1,3,4</sup>  |  
 Dmitry B. Veprintsev<sup>1,2</sup> 

<sup>1</sup>Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK

<sup>2</sup>Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK

<sup>3</sup>School of Computer Science, University of Birmingham, Birmingham, UK

<sup>4</sup>The Alan Turing Institute, London, UK

<sup>5</sup>MRC IMPACT Doctoral Training Programme, Universities of Birmingham, Leicester and Nottingham, Midlands, UK

<sup>6</sup>MSc Programme in Drug Discovery & Pharmaceutical Sciences, University of Nottingham, Nottingham, UK

<sup>7</sup>Department of Pharmacology, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain

<sup>8</sup>Bioaraba, Neurofarmacología Celular y Molecular, Vitoria-Gasteiz, Spain

## Correspondence

Mireia Jiménez-Rosés, Iain B. Styles and Dmitry B. Veprintsev, Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.

Email: [mireiajroses@gmail.com](mailto:mireiajroses@gmail.com); [i.b.styles@bham.ac.uk](mailto:i.b.styles@bham.ac.uk); [dmitry.veprintsev@nottingham.ac.uk](mailto:dmitry.veprintsev@nottingham.ac.uk)

## Funding information

BBSRC Doctoral Training Programme; COMPARE; COST action 18133 ERNEST short term scientific mission fellowship; EMBO short term fellowship; International Fellowship by the Office of Educational Affairs, Thailand; MRC IMPACT doctoral programme; Roche Postdoctoral Fellowship; Study Abroad Postgraduate Education Scholarship (YLSY)

## Abstract

G protein-coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them. Ligands exert their action via the interactions in the ligand binding pocket. We hypothesized that there is a common set of receptor interactions made by ligands of diverse structures that mediate their action and that among a large dataset of different ligands, the functionally important interactions will be over-represented. We computationally docked ~2700 known  $\beta$ 2AR ligands to multiple  $\beta$ 2AR structures, generating ca 75 000 docking poses and predicted all atomic interactions between the receptor and the ligand. We used machine learning (ML) techniques to identify specific interactions that correlate with the agonist or antagonist activity of these ligands. We demonstrate with the application of ML methods that it is possible to identify the key interactions associated with agonism or antagonism of ligands. The most representative interactions for agonist ligands involve K97<sup>2.68x67</sup>, F194<sup>ECL2</sup>, S203<sup>5.42x43</sup>, S204<sup>5.43x44</sup>, S207<sup>5.46x641</sup>, H296<sup>6.58x58</sup>, and

**Abbreviations:** AIF, atomic interaction fingerprint; BHO, Bayesian hyperparameter optimization; InChiKey, International Chemical Identifier Key; GPCRs, G protein-coupled receptors; MCC, Matthews correlation coefficient; ML, machine learning; MW, molecular weight; RFC, Random Forest Classifier; SHAP, Shapley Additive Explanations; SDF, spatial data file; TMs, transmembrane helices;  $\beta$ 2AR,  $\beta$ 2-adrenoceptor;  $\beta$ AR,  $\beta$ -adrenoceptors.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Pharmacology Research & Perspectives* published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

K305<sup>7.32×31</sup>. Meanwhile, the antagonist ligands made interactions with W286<sup>6.48×48</sup> and Y316<sup>7.43×42</sup>, both residues considered to be important in GPCR activation. The interpretation of ML analysis in human understandable form allowed us to construct an exquisitely detailed structure-activity relationship that identifies small changes to the ligands that invert their pharmacological activity and thus helps to guide the drug discovery process. This approach can be readily applied to any drug target.

#### KEYWORDS

adrenoceptor, docking, drug discovery, GPCRs, machine learning, structure-activity relationship

## 1 | INTRODUCTION


G-protein-coupled receptors (GPCRs) remain a therapeutically important family of proteins with over 100 receptors targeted by 500 drugs approved for clinical use.<sup>1</sup> The human  $\beta$ 2-adrenoceptor ( $\beta$ 2AR)<sup>2,3</sup> responds to stimulation by the endogenous agonist ligands adrenaline and noradrenaline by inducing Gs-mediated cAMP signaling and is a valuable target for small molecule smooth muscle relaxants used to treat asthma and other pulmonary diseases.<sup>4,5</sup> Endogenous agonist activity can be readily inhibited by so-called antagonist drugs that prevent receptor activation by occupying the binding pocket without activation and blocking agonist access. A large number of ligands have been developed to target  $\beta$ -adrenoceptors ( $\beta$ AR) over the last 60 years since the pioneering discovery of beta-blockers by Sir James Black.<sup>5-9</sup>

All GPCRs share a common architecture of a bundle of seven transmembrane helices (TMs), with the ligand binding pocket accessible from the extracellular space and an intracellular effector binding site that becomes available following transition into an active receptor conformation.<sup>10</sup> One of the key features of GPCRs is that they are highly dynamic and adopt many distinct conformations that are important for the engagement of signaling partners, e.g., activation of the Gs protein or arrestins.<sup>11</sup> It is generally thought that ligands control GPCR activity by preferentially stabilizing active or inactive conformations.<sup>12</sup> With 35 reported structures with 13 diverse ligands in inactive and active states reported,  $\beta$ 2AR is one of the best-studied GPCRs from a structural perspective.

Structure-based drug design has become an integral part of the modern drug discovery process. Approaches to link ligand structure to its activity are generally based on the ligand chemical structure (similar chemical structures have similar activity paradigms) or by considering the interactions between the ligand and the receptor. Structural Interaction Fingerprints that describe the interactions of ligands with proteins<sup>13-15</sup> have proven to be a very successful approach to score binding poses of ligands. A number of different interaction fingerprints have been developed, with more complex ones that incorporate atomic interactions and different types of non-covalent interactions having superior performance.<sup>16</sup> Several studies have attempted to link structural properties of the ligands and the interactions they make to the receptor to their functionality,

based on available crystallographic structures and complemented with ligand docking<sup>17,18</sup> or MD simulations.<sup>19</sup> These studies show significant promise in using interaction fingerprints to rationalize the link between structure and function, however, the results of these studies were limited to the experimentally available structural data that cover only a very small fraction of known  $\beta$ 2AR ligands. This limited their general ability to generate the new chemical knowledge needed to answer the key question in the drug discovery pipeline—what is the next molecule to make?

Ligands exert their action on GPCRs via the interactions they make in the ligand binding pocket. We hypothesized that despite the observed structural diversity of ligands targeting a particular receptor, there should be common interacting atoms within the ligand binding pocket that mediate their action. Unfortunately, the 35 experimentally determined structures is a very small dataset to obtain a comprehensive representation of the interaction pattern between ligands and the receptor. We reasoned that among a large dataset of different ligands and their respective binding poses, the functionally important atomic interactions the ligands make with a particular receptor will be over-represented. To investigate this hypothesis, we assembled a database of ~2700 known  $\beta$ 2AR ligands and computationally docked them to multiple experimentally determined  $\beta$ 2AR structures, generating ca 75 000 docking poses (Figure 1A,B). This produced a large synthetic dataset suitable for Machine Learning applications. For each of the docking poses, we generated a detailed Atomic Interaction Fingerprint (AIF), which comprises a list of all the pairs of atoms involved in the interaction between a receptor and a ligand and a classification of each pairwise interaction as one of fifteen types of bond. In total, there were ca 1100 possible interaction descriptors that we interchangeably call features (Figure 1C) in our dataset. Using pairwise correlation and Machine Learning (ML) approaches, we identified specific interactions between the ligands and the  $\beta$ 2AR that correlated with their reported agonist or antagonist activity at the receptor (Table S1). In addition to a common set of interactions that were present for both ligand types, agonists make specific contacts with the amino acid residues H93<sup>2.64×63</sup>, K97<sup>2.68×67</sup>, S203<sup>5.42×43</sup>, S204<sup>5.43×44</sup>, S207<sup>5.46×461</sup>, H296<sup>6.58×58</sup> and K305<sup>7.32×31</sup> in transmembrane helices TM2, TM5, TM6, and TM7 while antagonists make specific interactions with W286<sup>6.48×48</sup> and Y316<sup>7.43×42</sup> in TM6 and TM7. This approach successfully identifies the key features of



**FIGURE 1** Workflow of the project. (A) Source of beta-adrenoceptor ligands available at open access repositories which comprise our 2683 compound dataset. (B) Molecular docking of test ligands to active and inactive  $\beta$ 2AR structures was performed using Autodock Vina. (C) Interatomic interaction fingerprint (AIF) calculations were made using Arpeggio. In the case of the “filtered dataset”, the generated AIFs were filtered based on the presence of ionic interactions with D113<sup>3.32</sup> and N312<sup>7.39</sup>.

the ligands in terms of the individual interactions they make with the receptor to exert their pharmacological action.

Importantly, we were able to discover more subtle relationships where small changes to the ligand result in significant changes to

their pharmacology, the so-called *activity cliffs* encountered in every drug discovery program. This method represents a novel strategy for understanding the molecular mechanism of drug action on receptors and provides a valuable tool to guide the drug design process.

## 2 | MATERIALS AND METHODS

### 2.1 | Dataset preparation

A dataset was compiled using the primary open access repositories GPCRdb,<sup>20,21</sup> ChEMBL,<sup>22</sup> ZINC,<sup>23</sup> DrugBank,<sup>24</sup> and Guide to Pharmacology.<sup>25</sup> This dataset yielded a total of 2643 unique  $\beta$ 2AR ligands, of which 1317 have reported pharmacological action, while 1326 compounds are binders with undetermined activity profiles. We classify ligands with known activity as either agonists (including partial and full agonists) or antagonists (including inverse agonists).

Each ligand was assigned an internal ID (ranging from 1 to 2643), and its corresponding SMILES string (line notation encoding its molecular structure) and pharmacological action (agonist/antagonist/binder) were retrieved from the relevant databases. The International Chemical Identifier key (InChIKey) was used as a unique identifier to distinguish between ligands across the dataset.<sup>26</sup> Both InChIKey and physicochemical properties appended for all compounds were acquired using the software Open Babel v3.1.1.<sup>27</sup>

### 2.2 | Protein structures and ligand preparation and docking

The active-state protein coordinates were extracted from two crystal structures of human  $\beta$ 2AR bound to an ultrahigh-affinity agonist (BI-167107) coupled with the Gs protein<sup>28</sup> or/and with a G protein-mimicking nanobody (Nb6B9)<sup>29</sup> from the Protein Data Bank (PDB code: 3SN6 and 4LDE, respectively). The inactive-state protein coordinates were extracted from the human  $\beta$ 2AR bound to the inverse agonist carazolol (PDB code: 5JQH).<sup>30</sup>

Receptor structures were aligned to use the same grid box of  $22 \times 22 \times 32$  Å at the orthosteric binding site, protonated, and charged, yielding a protein input file for subsequent docking experiments using UCSF Chimera.<sup>31</sup>

The SMILES representation of ligands along with their internal ID were protonated and converted to a spatial data file (SDF) and pdbqt formats using Obabel.

The semi-flexible molecular docking was carried out using the software AutoDock Vina<sup>32</sup> and generated up to 10 poses for every compound. In total, 2643 compounds were docked in three  $\beta$ -adrenoceptor structures, yielding almost 27 000 docking poses.

### 2.3 | Interaction fingerprint calculations and filtering

The inter-atomic receptor-ligand interaction fingerprints (AIFs) were calculated for all docking poses generated for each compound using the software Arpeggio<sup>33</sup> executed in Docker environment,<sup>34</sup> a software container platform. This method accounts for the presence

of up to 15 subtypes of interatomic interactions, classified by atom type, distance, and angle constraints. The output was presented as binary values, with a 1 denoting the presence of a particular defined interaction and 0 indicating an absence.

A Python script was written to filter the Arpeggio results (to generate the "filtered dataset") by imposing minimum constraints that enforced certain features deemed essential for  $\beta$ 2AR ligand binding, which eliminated all irrelevant binding poses (around 50% rows). Criteria important for binding were based on prior knowledge derived from the literature, in particular the presence of the ionic/polar interaction between D113<sup>3,32</sup> and N312<sup>7,39</sup> with the ethanolamine moiety of the ligands.

### 2.4 | Generation of interaction matrix

A Python script was written to process each docking pose to generate a single  $M \times N$  matrix for each PDB, where  $M$  is ligand poses (samples as "ligand internal ID\_docking pose number") and  $N$  are the specific atomic interaction (features as "receptor residue number/interacting atom—ligand interacting atom and interaction type" (e.g. "lig 752\_04" and "301/O—N Polar," respectively), present in the whole ligand set. The value 1 corresponds to the occurrence of a particular type of interaction and 0 to the non-occurrence of a particular type of interaction. As the AIF files generated by Arpeggio only contained the interaction present for a particular docking pose, the imputation of missing data was handled by setting any undefined (NaN) values to 0. Finally, we excluded the three subtypes of interactions reported by Arpeggio: Clash, VdW Clash, and Proximal from subsequent analysis as they provided very little information but represented around 60% of the columns. We also included pharmacological action label ("agonist" or "antagonist", if known, or "binder" if not known) for each ligand binding pose in the same data table as an additional column.

### 2.5 | Descriptive statistical analysis

A descriptive statistical analysis of the frequency of the interatomic interactions was performed using a Python script. In this manner, the most frequently occurring features (those observed in at least 10% of all docking poses) contributing to agonism and antagonism were clearly identified across all interaction types and collated for further analysis. This resulted in the reduction of the number of features from ca 1100 to ca 100.

Subsequently, we computed the pairwise correlation between the columns representing atomic interactions and the column representing pharmacological action using Pearson's correlation coefficient ( $r$ ) method. The resulting value  $r$  for each interaction (feature) reflects how well it is correlated with the pharmacological action (agonism or antagonism). Plots, graphs, and tables were generated with Excel, and statistical significance was determined using an unpaired  $t$ -test using Prism 8.

## 2.6 | Machine learning dataset preparation

The dataset was then randomly shuffled and split, via stratification, into cross-validation and final hold-out datasets. The cross-validation set was used for training and validation during hyperparameter optimization. The hold-out dataset comprised 20% of the original dataset and allowed us to gauge whether the validation scores were good estimations of model performance when generalizing to unseen data. The hold-out set was not used during any training or optimization procedures.

## 2.7 | Model selection

### 2.7.1 | Performance metric

For the filtered dataset the Random Forest classifier and for the unfiltered dataset XGBoost classifier were used. Matthews correlation coefficient (MCC) was used as the performance metric for all models.<sup>35</sup> The MCC metric is defined as follows:

$$\text{MCC} = \frac{\text{TP} \times \text{TN} - \text{FP} \times \text{FN}}{(\text{TP} + \text{FP})(\text{TP} + \text{FN})(\text{TN} + \text{FP})(\text{TN} + \text{FN})}$$

where TP is the number of true positives, TN the number of true negatives, FP the number of false positives, and FN the number of false negatives. The MCC for binary classification weights both positive and negative classes equally, while also being robust to severe class imbalances. A value of +1 indicates a perfect positive correlation, that is a total agreement between prediction and observation. An MCC score of 0 indicates no correlation, that is the classifier performs no better than a random coin flip. Finally, -1 indicates a perfect negative correlation, that is a total disagreement between prediction and observation.

### 2.7.2 | Model performance estimation

Model performance was validated using repeated-stratified-k-fold cross-validation. Cross-validation entails splitting the dataset into  $k$  equally sized partitions, termed folds. One of the folds is extracted and used for validating a model on unseen data. The remaining folds are then used to train the model. This process is then repeated using each of the  $k$  folds as the validation set. The optimal model is the one that has the best performance on average across all  $k$ -folds. Cross-validation generally provides a less optimistic estimation of model generalizability on unseen data, which is finally tested on the hold-out set. Due to class imbalances in the data, stratification is used to ensure that the original distribution of classes is maintained in each fold, thus preventing any fold from being populated by a single class.<sup>36</sup> Model estimation can be noisy and so by performing cross-validation over many repeats one obtains a more precise estimation of true model performance. Bootstrap resampling was used to estimate model uncertainty.<sup>37</sup> Confidence intervals were calculated

with respect to a 99% confidence level. Bayesian hyperparameter optimization (BHO) was utilized to determine high-performing model parameter configurations when tested on unseen data. BHO was set to maximize the mean MCC across  $K$ -folds and repeats, model uncertainty was then calculated using optimized models only.

#### Random forest classifier hyper parameters

Hyperparameter name	Hyperparameter value
Criterion	Gini
Estimators	2000
Max depth	5
Max-features	5
Splitter	Best
Minimum samples split	2
Minimum samples leaf	1
Minimum weighted fraction leaf	0
Maximum leaf nodes	Unlimited
Minimum impurity split	None
Minimum impurity decrease	None

#### XGBoost hyper parameters

Hyperparameter name	Hyperparameter value
Eta	0.4306
gamma	0.2458
Learning rate	0.05873
Max delta step	7
Max depth	8
Minimum child weight	1.246
Number of estimators	1150
Scale positive weight	1
Subsample	0.7532

All other hyperparameters for XGBoost that are not specified were kept at their default values according to the XGBoost API guide (<https://xgboost.readthedocs.io/en/latest/parameter.html>).

### 2.7.3 | Model feature importance analysis

The most important atomic interactions, for classifying agonist or antagonist ligands, were identified using the Shapley Additive Explanations (SHAP) method.<sup>38</sup> Shapley values are based upon coalition game theory and inform one how to fairly distribute the prediction of a model among the features. The Shapley value for one feature is the average marginal contribution of a feature value across all the possible combinations of features. More concretely, the Shapley value assigns an importance to each feature by calculating the effect on model prediction when including a particular feature compared to the model prediction when the feature is withheld. Mathematically this can be formalized as:

$$\phi_i = \sum_{S \subseteq M \setminus i} \frac{|S|!(|M| - |S| - 1)!}{|M|!} [f(S \cup i) - f(S)],$$

where  $S$  refers to a subset of features that does not contain the feature for which we are calculating  $\phi_i$ .  $S \cup i$  is the subset that contains features in  $S$  and feature  $i$ . Finally,  $S \subseteq M \setminus i$  represents all sets  $S$  that are subsets of the total set of features  $M$ , excluding feature  $i$ . The computation time increases exponentially with the number of features; thus we used the TreeSHAP algorithm that approximates SHAP values for tree-based machine learning models in polynomial time.<sup>39</sup> The main motivations for using the SHAP feature importance method over other popular methods, such as Gini and Permutation methods, is due to the following:

**Consistency:** The Gini feature importance method is susceptible to producing inconsistent feature importances that are biased to the specific ordering of features specified by their position, as split nodes, in the tree. TreeSHAP method is equivalent to averaging differences in model predictions over all possible orderings of the features and thus does not suffer from such inconsistencies.

**Granular Interpretability:** Although permutation importance is not biased to the specific structure of decision trees it only provides a global understanding of the most important features. With TreeSHAP, observations get their own set of SHAP values and, therefore, we can understand feature importance on a per sample basis.

### 2.7.4 | Determining the optimal number of repeats

There is an exponential relationship between the number of times one has to repeat bootstrap or cross-validation and the level of precision to within which one would like to measure true model performance. This leads to a trade-off between the precision and time complexity of model performance estimation. We thus estimate the optimal number of repeats to use for Bootstrap and cross-validation resampling methods to an acceptable level of precision as:

$$n = z_a^2 \left( \frac{\sigma^2}{\delta^2} \right)$$

where  $z$  is the ordinate on the Normal distribution curve that corresponds to a particular level of confidence we have in our estimation, denoted  $\alpha$ .  $\sigma$  is the population standard deviation, and  $\delta$  is the specified precision of the estimate. We estimate the population standard deviation via repeated bootstrap resampling, thus each estimate of the number of repeats is specific to the variance of each model and its hyperparameter configuration (<https://www.itl.nist.gov/div898/handbook/ppc/section3/ppc333.htm>).

A precision of 1% (Marginal Error = 0.01) was selected for all resampling methods (Figure S1). Therefore, a minimum of 13 repeats for both the RFC and XGBoost were used during cross-validation and bootstrap resampling.

## 2.8 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY,<sup>3</sup> and are permanently archived in the Concise Guide to PHARMACOLOGY 2021/22.<sup>2</sup>

## 3 | RESULTS

### 3.1 | $\beta$ 2AR agonists are on average bigger and more lipophilic compared to antagonists


To construct our dataset of currently known  $\beta$ 2AR ligands we searched all available open access repositories such as GPCRdb, ChEMBL, DrugBank, Guide to Pharmacology, and ZINC. The curated database included 2683 unique  $\beta$ 2AR ligands, of which 1317 had reported pharmacological action (987 agonists and 330 antagonists/inverse agonists). The remaining 1366 were classified as “known binders” with no assigned pharmacological activity (Figure 1A).

To understand if there are any obvious differences between agonists and antagonists, we compared their physicochemical (PC) properties predicted using OpenBabel software.<sup>27</sup> We found that many PC property values for agonists were statistically different from those for antagonists (unpaired  $t$ -test,  $p < .0001$ ), for example, molecular weight (MW) and lipophilicity (logP). The MW of ~70% of agonist ligands was in the 350–550 g/mol range, with an average of  $469 \pm 108$  g/mol. In contrast, the antagonist ligands were typically smaller, with ~70% within a range of 200–400 g/mol (average  $358 \pm 108$  g/mol). The logP values of ~70% of agonists are in the range 3–7, with an average of  $4.6 \pm 1.6$ , whereas ~70% of antagonist ligands had logP values in the range 0–5 (average  $3.1 \pm 1.4$ ). Taken together, the  $\beta$ 2AR agonists profiled here tended to be more lipophilic and bigger in size. On the contrary, endogenous agonists adrenaline and noradrenaline are small and water-soluble, suggesting that size and lipophilicity are not an intrinsic prerequisite of all agonists. We observed an identical linear correlation between the molecular weight and lipophilicity for both agonists and antagonists (Figure 2), suggesting that bigger compounds are more lipophilic. The likely explanation is that drug discovery efforts have focused on developing  $\beta$ 2AR agonists formulated for the treatment of asthma. They are delivered to the lungs via inhalation with higher hydrophobicity increasing their duration of action at the target tissue. Therefore, although the observed differences in size and hydrophobicity are present in our data set, they are unlikely to have a functional role.

### 3.2 | Generating atomic interaction fingerprints based on molecular docking poses

To obtain structural information on how ligands in the curated dataset interact with the receptor (i.e., ligand binding poses), we

**FIGURE 2** Physicochemical (PC) properties of the ligands (agonist in blue and antagonist in orange) predicted using OpenBabel software. Correlation between lipophilicity and molecular weight. Spearman correlation coefficient is 0.62 for agonist and 0.76 for antagonists.



performed molecular docking using the open-source AutoDock Vina software.<sup>32</sup> For performance reasons, AutoDock Vina uses a semi-rigid docking approach where the ligand is flexible but the receptor is rigid. In nature, they are both dynamic but this has the potential to create a very large conformational space that is impossible to enumerate, and the answers have to be learned from a limited number of examples. We included three representative  $\beta$ 2AR structures in our study: the active conformational states (i) PDB 3SN6 stabilized by the Gs protein<sup>28</sup> and (ii) PDB 4LDE stabilized by a nanobody,<sup>29</sup> and (iii) the inactive conformational state PDB 5JQH.<sup>30</sup>

We obtained ~75 000 binding poses in total, ~25 000 poses for each PDB (up to 10 poses for ligand, for 2683 compounds) (Figure 1B). Each ligand binding pose was used to generate an atomic interaction fingerprint (AIF) using Arpeggio software,<sup>33</sup> in total we obtained ~75 000 AIF files (Figure 1C). Each AIF included ~60 unique interactions on average between the atoms of the ligand and atoms of the receptor. When the type of atoms of each ligand and the type of bond formed are considered, this resulted in over 1100 possible types of interaction across the complete ligand dataset.

It is important to consider that the obtained AIF fingerprint dataset contains noise because not all of the predicted docking poses are likely to be relevant or functionally important. The limitations of the ligand docking algorithms result in multiple alternative binding poses with very similar “quality scores”, with only one of the top ten solutions likely to correspond to the experimentally observed binding pose. While crystallographic structures typically represent one ligand binding pose, they tend to represent the lowest energy state of the system. On the contrary, molecular dynamics simulation and biophysical experiments suggest that ligands are dynamic when bound to the receptor.<sup>40</sup> Therefore, it is important to consider multiple ligand docking poses in the analysis. We rationalized that in a large dataset of different ligands and their respective binding poses, the functionally important atomic interactions between the ligands and the receptor will be over-represented while the influence of the noise (irrelevant binding poses) would average out.

We improved the signal-to-noise ratio within our dataset by excluding irrelevant binding poses using prior knowledge based

on crystallographic data (Figure 1C, filtering panel). The majority (ca 97%) of  $\beta$ 2AR ligands have a prevalent  $\beta$ -hydroxy-amine motif that makes specific interactions with the receptor. We, therefore, excluded poses that did not display this ionic interaction between the oxygen of D113<sup>3.32</sup> $\times$ <sup>32</sup> and the nitrogen atom of ethanolamine of the ligands and the hydrogen bond between the oxygen atom of N312<sup>7.39</sup> $\times$ <sup>38</sup> and either the NH or beta-hydroxyl groups in the ligand scaffold; these have been observed in every experimental crystallographic structure of the  $\beta$ 2AR. After applying this filter, we obtained ~31 500 atomic interaction files (~10 500 poses and AIF files for each PDB), reducing the size of the original dataset by ~55%. We refer to this as the “filtered dataset.” As the filtering step also removed ~3% of ligands in our dataset that did not contain the  $\beta$ -hydroxy-amine motif or did not produce suitable poses, we have also included in our analysis the “full dataset” consisting of ~75 000 AIF files with no filtering for comparison.

### 3.3 | Data-driven analysis reveals key interactions that drive agonism and antagonism of ligands

We constructed a ligand-receptor interaction matrix, organizing the atom-atom interactions and their types in the columns and each binding pose in rows for each PDB. We defined the ligand binding site as all residues that interact with at least one ligand binding pose in the dataset resulting in 30 residues in total (Table S2). The atoms of the ligand binding site provide a constant reference coordinate system to describe ligand-receptor interactions. We defined atomic interaction between specific atoms of the receptor, the specific atom (C, N, O, etc) in the ligand, and the nature of the interacting bond (polar, ionic, hydrophobic, etc). This strategy allowed us to encode the ligand-receptor interaction matrix that accommodates diverse ligands irrespective of their structural scaffold.

Using Pearson's pairwise correlation between the independent variables describing the presence or absence of an atomic interaction and the dependent variable denoting agonist/antagonist properties of the ligands, we identified atom-atom interactions (or

features) that are associated with agonism or antagonism in the filtered dataset. From about 100 commonly observed interactions, we find that the most representative interactions for agonist ligands are hydrophobic/aromatic contacts involving K97<sup>2.68×67</sup>, F194<sup>ECL2</sup>, H296<sup>6.58×58</sup>, and K305<sup>7.32×31</sup> and polar/ionic/hydrogen bond contacts with S203<sup>5.42×43</sup>, S204<sup>5.43×44</sup>, S207<sup>5.46×641</sup>, and H296<sup>6.58×58</sup>. The antagonists made specific hydrophobic/aromatic contacts with W286<sup>6.48×48</sup> and Y316<sup>7.43×42</sup> and polar/ionic/hydrogen bond contacts with Y316<sup>7.43×42</sup> (Figure 3A and Table S3).

While the majority of interactions had the same impact on receptor function (mediating agonism or antagonism) for all atoms of the individual residue, in some cases (D113<sup>3.32×32</sup>, D192<sup>45.51×51</sup>, F193<sup>45.52×52</sup>, T195<sup>ECL2</sup>, F289<sup>6.51×51</sup>, F290<sup>6.52×52</sup>, Y308<sup>7.35×34</sup>, N312<sup>7.39×38</sup>) this depended on the individual atoms of the residue and the nature of the interacting bond (Table S3). For example, the polar/ionic/hydrogen contact of the carbonyl oxygen (OD1, as defined by the Protein Data Bank format<sup>41</sup>) of D113<sup>3.32×32</sup> with an oxygen atom of a ligand is predictive of agonism while interaction with a nitrogen atom is predictive of antagonism. Contacts made by hydroxyl oxygen (OD2) of D113<sup>3.32×32</sup> have the opposite effect: interaction with a nitrogen atom of the ligand corresponds to agonism, while interaction with an oxygen atom results in antagonism. In another example, polar contacts of the sidechain nitrogen (ND2) of N312<sup>7.39×38</sup> with oxygen atoms in the ligand corresponded to agonism while interaction with nitrogen leads to antagonism.

The full dataset was a more complex challenge as it contains more noise in terms of the number of different poses and also a more diverse range of ligands. Nonetheless, we also observed around 100 common interactions, which were mostly the same as those determined for the filtered dataset. However, several interactions changed their relative importance (Figure 3B); for example, the importance of S204<sup>5.43×44</sup> as a determinant of agonism was reduced, while W313<sup>7.40×39</sup> became more predictive of agonism. However, the core set of agonist-associated interactions made with S203<sup>5.42×43</sup>, S207<sup>5.46×461</sup>, and, F194<sup>ECL2</sup>, H296<sup>6.58×58</sup>, K305<sup>7.32×31</sup>, and K97<sup>2.68×67</sup> remained the same.

To validate the performance of the Pearson's pairwise correlation, we computed the maximum Matthews Correlation Coefficient (MCC) which measures the quality of binary classifications when the classes are of different sizes as in our case (ca 75% are agonists). For the filtered dataset, taking the maximum MCC with a cut-off score of 0.37, we obtained a pharmacological classification (agonist or antagonist) with a MCC of 0.43 which corresponds to the accuracy of prediction of 79% (Figure S2A). For the full dataset (cut-off = 0.51), the MCC and accuracy decreased to 0.29 and 67%, respectively (Figure S2B). An important consideration for interpretation of the prediction accuracy is that the training dataset may contain errors: compounds that are "wrongly" assigned to a particular class (e.g., agonist or antagonist). Therefore, we would not expect the predictors to be 100% accurate during the validation step.

As the pairwise correlation approach identifies the relative importance of individual interactions, we applied ML strategies (see

methods for details) that can detect more complex patterns in the data than pairwise correlation analysis. We trained a Random Forest Classifier (RFC)<sup>42</sup> on the filtered dataset and XGBoost<sup>43</sup> on the full dataset. RFC constructs a multitude of decision trees and averages them to improve the predictive performance and control overfitting, reaching MCC values in the training of 0.81 and an accuracy of 92% on the filtered dataset (Figure S3 and S5A). The XGBoost algorithm that iteratively constructs optimized decision trees guided by the results of the previous steps performed remarkably well on the full dataset (Figure S4 and S5B), with a prediction performance on the holdout set of 0.78 MCC and 93% accuracy after full Bayesian optimization. This suggests that there are predictive patterns in both the filtered and full datasets not captured by a simple predictor based on pairwise correlations.

It is, however, a considerable challenge to interpret what the ML algorithms have actually learned. We extracted the feature importance for RFC trained on the filtered dataset (Figure 4A,B) and the feature importance for XGBoost trained on the full dataset (Figure 4C,D), using the Shapley Additive Explanations (SHAP) values which reflect the contribution of each feature to the prediction. In most cases, the presence of a particular interaction is predictive of agonism or antagonism. However, in a minority of cases, the absence of the interaction was more important for predictions (e.g., 193/CB--1/C hydrophobic).

Overall, while the relative order of importance of individual features varied depending on the model, we observed the same set of interactions that were predictive of agonism or antagonism for both models (Table S4). The application of pairwise correlation analysis and ML methods allowed us to identify the key interactions associated with agonism or antagonism of ligands (Figures 3 and 5).


## 4 | DISCUSSION

While an observation that on average agonists are larger and more hydrophobic could potentially be used to distinguish them from antagonists in the  $\beta$ AR ligand dataset, the pharmacological action of ligands on GPCRs is far more specific than a simple function of their size or hydrophobicity.


### 4.1 | Specific ligand-receptor interactions determine their pharmacological activity

While ML algorithms can successfully classify compounds into agonists and antagonists, understanding what their decision is based on and translating this information into a language humans can understand is crucial for their usefulness for drug discovery.<sup>44</sup> Studying the ligand binding poses of thousands of ligands docked in the  $\beta$ 2AR binding pocket allowed us to identify the key ligand-receptor interactions which dictate a molecule's propensity to cause agonism or antagonism. The structurally diverse nature of the test set that

## (A) FILTERED DATASET



## (B) FULL DATASET




**FIGURE 3** Schematic representation of the interactions predicted using the pairwise correlation approach. (A) filtered dataset and (B) full dataset. The type of interaction is summarized in squared shape for hydrophobic and aromatic contacts, round shape for the polar, ionic, and hydrogen bond contacts, and a combination of both. The dotted purple lines represent ionic and/or hydrogen bond contacts. The ethanolamine moiety of the BI-167107 ligands is highlighted in light blue.

consisted of all ligands with reported activity in publicly accessible databases allowed us to identify several “hot spots” mediating the agonism or antagonism of ligands acting on  $\beta$ 2AR. Agonism was mediated by residues in TM2 and TM5 and further facilitated by residues in TM6 and TM7. It is entirely plausible that certain ligands can successfully pull these TM regions together causing receptor activation in the process. In contrast, our data suggest that antagonism is mediated by the interaction of ligands with W286<sup>6.48</sup><sup>48</sup>, the so-called toggle switch, that has long been proposed to play a key role in the activation of GPCRs.<sup>45,46</sup> The second mediator of antagonism is Y316<sup>7.43</sup><sup>42</sup> which is involved in the so-called 3–7 lock that has previously been identified as important for GPCR activation.<sup>47</sup> Engaging these key residues in the ligand binding pocket likely prevent the conformational rearrangements necessary for activation of the receptor.


## 4.2 | Potential for developing more fine-grained models of ligand activity

While the assembled data classify compounds as agonist or antagonist, the pharmacological activity of compounds covers a spectrum from a very strong antagonist (aka inverse agonist) to that of a very strong agonist (aka full agonist). Another class of GPCR ligands, so-called biased ligands, changes the balance between activating G protein and arrestin signaling pathways, with a potential to increase their therapeutic benefits.<sup>11,48</sup> It is likely that such partial and biased ligands would also show a distinct AIF that is somewhat different from the all-inclusive agonist AIF we have identified in the current work. However, a large experimental dataset of partial or biased agonists would be needed to explore this hypothesis, ideally collected in a uniform screen to minimize experimental and interpretational bias.




**FIGURE 4** Feature importance of the RFC (A, B) and XGBoost ML (C, D) models applying the SHAP value method. (A, C) The x-axis is the average magnitude change in model output when a feature is “hidden” from the model. Higher SHAP values indicate higher importance of the feature. (B, D) Local SHAP values per sample (each ligand pose) are sorted by the mean absolute SHAP value method. Gray represents a value of 0, thus indicating the absence of a particular atomic interaction for a specific sample. Black represents a value of 1, thus indicating the presence of a particular atomic interaction for a specific sample. The x-axis shows how the presence or absence of an atomic feature increases or decreases the likelihood of a sample being classified as an antagonist. The data are plotted for all samples in the dataset, showing the distribution of important values. The units of the x-axis using RFC and XGBoost are log odds.

## (A) FILTERED DATASET (RFC)



## (B) FULL DATASET (XGBoost)



**FIGURE 5** Schematic representation of the interactions for the machine learning approach. (A) RFC for the filtered dataset and (B) XGBoost for the full dataset. The type of interaction is summarized in squared shape for hydrophobic and aromatic contacts, round shape for the polar, ionic, and hydrogen bond contacts, and a combination of both. The dotted purple lines represent ionic and/or hydrogen bond contacts. The black outlines represent the atomic interactions with higher feature importance. The ethanolamine moiety of the BI-167107 ligands is highlighted in light blue.

The analysis of the learning performance of RFC and XGBoost classifiers (Figure S5) suggests that reasonable performance is achieved with a limited dataset (ca 300–450 compounds), although further increases in the dataset size resulted in improved performance. It is likely that an even larger dataset would be required to predict continuous rather than a binary structure-activity relationship from AIFs.

Our methodology can be readily applied to any receptor (or drug target) for which an extensive set of ligands has been developed and characterized, and where *in silico* docking experiments can be performed. This can include data already in the public domain or through examining the results of an *in house* (e.g., commercial) drug-target screening campaign. The advantage here is that in many cases the same signaling assay will have been used to profile all the compounds, improving the consistency of the dataset. This would allow the relative importance of each atom-atom interaction to be

assessed as a modifier of signaling output. Also, it may be possible to isolate functional readouts (e.g.,  $\beta$ -arrestin versus G protein) and therefore make predictions about functional bias. Further tantalizing possibilities include the use of automated internet metasearch of publications and patents to assemble such datasets and reduce the number of compounds described as “known binders” if they are not available yet.

### 4.3 | Potential for developing predictors of pharmacological activity for novel ligands

Being able to understand which atoms of the ligand drive agonist or antagonist activity significantly increases the value of *in silico* docking campaigns. Importantly, it opens doors to a more rational engineering of ligands with improved and optimized pharmacological

properties—facilitating the design of new ligands not present in the large virtual libraries and thus opening up a chemical space many orders of magnitude larger than the largest virtual libraries available.

From a computation perspective, it is a relatively straightforward task to generate a prediction of ligand pharmacological activity based on the model learned and the predicted binding pose of the ligand and the corresponding AIF. However, large-scale docking experiments produce multiple possible ligand binding poses, and the existing scoring functions do not allow for reliable identification of the “correct” binding pose. The structural diversity of the ligands complicates the analysis even further as overlaying the predicted binding pose with the available experimental data is not always informative.

#### 4.4 | Limitations on the ability to correctly predict ligand activity

Our data strongly support the hypothesis that individual atomic interactions are correlated with ligand pharmacological activity. This is learned from a large dataset of ligand binding poses, where “correct” binding poses are a minority but the machine learning methods we used identified the structure-activity relationship because “wrong” binding poses averaged themselves out. Prediction of pharmacological activity, in contrast, is 100% dependent on having a correct binding pose for the ligand. This is a problem that has not yet been solved in a satisfactory manner, and it limits the performance of any structure-based activity prediction method. It is clear that the future progress in our ability to predict the pharmacological activity of novel ligands will be closely correlated with our ability to correctly predict their ligand binding poses. The analysis of the structural properties of ligands (Figure S6) with “correct” and “wrong” predicted activity did not identify any specific clusters of ligands for which the prediction failed. This observation supports the idea that the quality of prediction is determined by the quality of the binding pose prediction. To summarize, the observed correlations are informative and potentially useful to design novel ligands with desired pharmacological, their application in a completely automated pipeline needs further optimization of docking algorithms.

## 5 | CONCLUSIONS

These results strongly support the hypothesis that the interatomic interactions between the receptor and its ligands are central to differentiate between their agonist and antagonist effects at the  $\beta$ 2AR. The overview obtained of the interatomic interactions between receptor and ligand which correlate with an action will help the synthesis of new previously unseen compounds with a specific pharmacological activity. While the specific interatomic interactions

between  $\beta$ 2AR and its ligands that we describe are unlikely to be generalizable to other GPCRs (with the exception of closely related receptors such as  $\beta$ 1AR), the same hypothesis and ML approach can be applied to other targets. The growth of GPCR ligand databases provides a rich data source to facilitate the application of this approach to other GPCRs, while conceptually this approach could be applied to any drug target.

The ability to predict the pharmacological action of a ligand based on its ligand binding pose will significantly advance drug discovery projects contributing to a reduction of attrition during drug development. The tools presented have the potential to focus the efforts of chemists proposing new candidate molecules based on existing scaffolds and offer the opportunity to identify completely new scaffolds that may be more amenable to modifications from large-scale docking experiments, thus opening up a chemical space of many orders of magnitude larger than the largest virtual libraries available.

#### AUTHORS' CONTRIBUTIONS

MJ-R, IBS, and DBV participated in research design. MJ-R, BAM, MJS, TDZT, RS, AB, LB-R, PH, SAC, CRH, EJK and, DAS conducted experiments and performed data analysis. All authors wrote or contributed to draft the manuscript.

#### ACKNOWLEDGMENTS

We thank Michael Stokes, Jill Baker, Uwe Grether, Arne Rufer, and Wolfgang Guba for valuable advice and stimulating discussions. We thank the research community of the European Cooperation in Science and Technology (COST) Action CA18133 “European Research Network on Signal Transduction” (ERNEST) for the continued support. MJR was funded by COMPARE. BAM, CRH, and SAC are funded by the MRC IMPACT doctoral program. DAS is funded by the Roche Postdoctoral Fellowship. PH is funded by an international fellowship awarded by the Office of Educational Affairs, Thailand. AB is funded by the Study Abroad Postgraduate Education Scholarship (YLSY) awarded by the Republic of Turkey Ministry of National Education. LBR was funded by EMBO short-term fellowship and the COST action 18133 ERNEST short-term scientific mission fellowship. MJS was funded by the BBSRC Doctoral Training Programme, the University of Nottingham and COMPARE.

#### CONFLICT OF INTEREST

DAS and DBV are founders of Z7 Biotech Ltd, an early-stage drug discovery company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

#### ETHICAL STATEMENT

This study did not involve animals, human tissue, human participants or identifiable personal information.

## DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

## ORCID

Mireia Jiménez-Rosés  <https://orcid.org/0000-0002-4049-8670>

Eline J. Koers  <https://orcid.org/0000-0002-5352-9069>

David A. Sykes  <https://orcid.org/0000-0002-6606-888X>

Iain B. Styles  <https://orcid.org/0000-0002-6755-0299>

Dmitry B. Veprintsev  <https://orcid.org/0000-0002-3583-5409>

## REFERENCES

- Hauser AS, Chavali S, Masuho I, et al. Pharmacogenomics of GPCR drug targets. *Cell*. 2018;172:41-54.e19. doi:10.1016/j.cell.2017.11.033
- Alexander SPH, Christopoulos A, Davenport AP, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. *Br J Pharmacol*. 2021;178(S1):S27-S156. doi:10.1111/bph.15538
- Harding SD, Armstrong JF, Faccenda E, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials. *Nucleic Acids Res*. 2022;50(D1):D1282-D1294. doi:10.1093/nar/gkab1010
- Shore SA, Moore PE. Regulation of beta-adrenergic responses in airway smooth muscle. *Respir Physiol Neurobiol*. 2003;137(2-3):179-195. doi:10.1016/s1569-9048(03)00146-0
- Cazzola M, Calzetta L, Matera MG.  $\beta$ 2-adrenoceptor agonists: current and future direction. *Br J Pharmacol*. 2011;163(1):4-17. doi:10.1111/j.1476-5381.2011.01216.x
- Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic Betareceptor antagonist. *Lancet*. 1964;1(7342):1080-1081. doi:10.1016/s0140-6736(64)91275-9
- Frishman WH. Beta-adrenergic blockers: a 50-year historical perspective. *Am J Ther*. 2008;15(6):565-576. doi:10.1097/MJT.0b013e318188bdca
- Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma. *Respir Med*. 2019;156:47-52. doi:10.1016/j.rmed.2019.08.005
- Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. *F1000Research*. 2019;8. doi:10.12688/f1000research.19811.1
- Hilger D, Masurel M, Kobilka BK. Structure and dynamics of GPCR signaling complexes. *Nat Struct Mol Biol*. 2018;25(1):4-12. doi:10.1038/s41594-017-0011-7
- Kenakin T, Miller LJ. Seven transmembrane receptors as shape-shifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. *Pharmacol Rev*. 2010;62(2):265-304. doi:10.1124/pr.108.000992
- Hilger D, Kumar KK, Hu H, et al. Structural insights into differences in G protein activation by family A and family B GPCRs. *Science*. 2020;369(6503):eaba3373. doi:10.1126/science.aba3373
- Marcou G, Rognan D. Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. *J Chem Inf Model*. 2006;47(1):195-207. doi:10.1021/ci600342e
- Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFT): a novel method for analyzing three-dimensional protein-ligand binding interactions. *J Med Chem*. 2004;47(2):337-344. doi:10.1021/jm030331x
- Kelly MD, Mancera RL. Expanded interaction fingerprint method for analyzing ligand binding modes in docking and structure-based drug design. *J Chem Inf Comput Sci*. 2004;44(6):1942-1951. doi:10.1021/ci049870g
- Jasper JB, Humbeck L, Brinkjost T, Koch O. A novel interaction fingerprint derived from per atom score contributions: exhaustive evaluation of interaction fingerprint performance in docking based virtual screening. *J Chem*. 2018;10(1):15. doi:10.1186/s13321-018-0264-0
- Kooistra AJ, Vischer HF, McNaught-Flores D, Leurs R, de Esch IJ, de Graaf C. Function-specific virtual screening for GPCR ligands using a combined scoring method. *Sci Rep*. 2016;6:28288. doi:10.1038/srep28288
- Kooistra AJ, Leurs R, de Esch IJ, de Graaf C. Structure-based prediction of G-protein-coupled receptor ligand function: a beta-Adrenoceptor case study. *J Chem Inf Model*. 2015;55(5):1045-1061. doi:10.1021/acs.jcim.5b00066
- Chan HC, Filipek S, Yuan S. The Principles of Ligand Specificity on beta-2- adrenergic receptor. *Sci Rep*. 2016;6:34736. doi:10.1038/srep34736
- Pandy-Szekeres G, Munk C, Tsonkov TM, et al. GPCRdb in 2018: adding GPCR structure models and ligands. *Nucleic Acids Res*. 2018;46(D1):D440-D446. doi:10.1093/nar/gkx1109
- Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. *Nat Rev Drug Discov*. 2017;16(12):829-842. doi:10.1038/nrd.2017.178
- Mendez D, Gaulton A, Bento AP, et al. ChEMBL: towards direct deposition of bioassay data. *Nucleic Acids Res*. 2019;47(D1):D930-D940. doi:10.1093/nar/gky1075
- Irwin JJ, Shoichet BK. ZINC – a free database of commercially available compounds for virtual screening. *J Chem Inf Model*. 2005;45(1):177-182. doi:10.1021/ci049714+
- Wishart DS. DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res*. 2006;34(90001):D668-D672. doi:10.1093/nar/gkj067
- Armstrong JF, Faccenda E, Harding SD, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: Extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY. *Nucleic Acids Res*. 2019;48:D1006-D1021. doi:10.1093/nar/gkz951
- Heller S, McNaught A, Stein S, Tchekhovskoi D, Pletnev I. InChI – the worldwide chemical structure identifier standard. *J Cheminform*. 2013;5(1):7. doi:10.1186/1758-2946-5-7
- O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. *J Cheminform*. 2011;3:33. doi:10.1186/1758-2946-3
- Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature*. 2011;477(7366):549-555. doi:10.1038/nature10361
- Ring AM, Manglik A, Kruse AC, et al. Adrenaline-activated structure of beta2- adrenoceptor stabilized by an engineered nanobody. *Nature*. 2013;502(7472):575-579. doi:10.1038/nature12572
- Staus DP, Strachan RT, Manglik A, et al. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation. *Nature*. 2016;535(7612):448-452. doi:10.1038/nature18636
- Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem*. 2004;25(13):1605-1612. doi:10.1002/jcc.20084
- Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem*. 2010;31(2):455-461. doi:10.1002/jcc.21334
- Jubb HC, Higuero AP, Ochoa-Montano B, Pitt WR, Ascher DB, Blundell TL. Arpeggio: a web server for calculating and Visualising interatomic interactions in protein structures. *J Mol Biol*. 2017;429(3):365-371. doi:10.1016/j.jmb.2016.12.004

34. Merkel D. Docker: Lightweight Linux containers for consistent development and deployment. *Linux J.* 2014;239(2):2.
35. Matthews BW. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. *Biochim et Biophys Acta.* 1975;405(2):442-451. doi:10.1016/0005-2795(75)90109-9
36. Vanwinckelen G, Blockeel H. On estimating model accuracy with repeated cross-validation. *BeneLearn 2012: Proceedings of the 21st Belgian-Dutch Conference on Machine Learning;* 2012:39-44.
37. Efron B, Tibshirani R. *An Introduction to the Bootstrap. Monographs on Statistics and Applied Probability.* Vol XVI. Chapman & Hall; 1993:436S.
38. Lundberg S, Lee S-I. A unified approach to interpreting model predictions. *arXiv.* 2017. doi:10.48550/arXiv.1705.07874
39. Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding with explainable AI for trees. *Nat Mach Intell.* 2020;2(1):56-67. doi:10.1038/s42256-019-0138-9
40. Rodríguez-Espigares I, Torrens-Fontanals M, Tiemann JKS, et al. GPCRmd uncovers the dynamics of the 3D-GPCRome. *Nat Methods.* 2020;17(8):777-787. doi:10.1038/s41592-020-0884-y
41. Berman HM. The protein data bank. *Nucleic Acids Res.* 2000;28(1):235-242. doi:10.1093/nar/28.1.235
42. Ho TK Random decision forests. 1995:278-282. doi:10.1109/icdar.1995.598994
43. Chen T, Guestrin C. XGBoost: a scalable tree boosting system 2016:785-794. doi:10.1145/2939672.2939785
44. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. *Nat Mach Intell.* 2020;2(10):573-584. doi:10.1038/s42256-020-00236-4
45. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA.  $\beta$ 2Adrenergic receptor activation. *J Biol Chem.* 2002;277(43):40989-40996. doi:10.1074/jbc.M206801200
46. Visiers I, Ballesteros JA, Weinstein H. Three-dimensional representations of G protein-coupled receptor structures and mechanisms. *Methods Enzymol.* 2002;343:329-371.
47. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. Action of molecular switches in GPCRs - theoretical and experimental studies. *Curr Med Chem.* 2012;19(8):1090-1109. doi:10.2174/092986712799320556
48. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. *Nat Rev Drug Discov.* 2013;12(3):205-216. doi:10.1038/nrd3954

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Jiménez-Rosés M, Morgan BA, Jimenez Sigstad M, et al. Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on  $\beta$ 2 adrenoceptor. *Pharmacol Res Perspect.* 2022;10:e00994. doi:10.1002/prp2.994